Analystreport

Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating.

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806